Source: Virtual Congress 2021 – Challenges and advances in the diagnosis and clinical management of tuberculosis



Rating:

Share or cite this content

Citations should be made in the following way:
T. Butova (Merefa, Ukraine), M. Kuzhko (Kiev, Ukraine), M. Gumeniuk (Kiev, Ukraine), O. Raznatovska (Zaporizhzhia, Ukraine), A. Tkachenko (Kharkiv, Ukraine), O. Borysova (Kharkiv, Ukraine), D. Butov (Kharkiv, Ukraine). Effectiveness of inhaled hypertonic saline application for sputum induction to improve Mycobacterium tuberculosis identification in patients with pulmonary tuberculosis. 1048

Member's Comments

No comment yet.

Related content which might interest you: A small audio device may be alternative to hypertonic saline inhalation for sputum induction in patients with pulmonary tuberculosis Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis Year: 2008 Role of 2-month sputum smears in predicting culture conversion in pulmonary tuberculosis Source: Eur Respir J 2011; 37: 376 Year: 2011 Results of drug susceptibility testing of Mycobacterium tuberculosis isolated from sputum and surgical material from pulmonary tuberculosis patients Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Outcomes of hypertonic saline inhalation as a treatment modality in nontuberculous mycobacterial pulmonary disease Source: Eur Respir J, 54 (1) 1802143; 10.1183/13993003.02143-2018 Year: 2019 Intravenous ozon in pulmonary tuberculosis Source: Eur Respir J 2005; 26: Suppl. 49, 650s Year: 2005 A cross-over study to compare the Lung Flute™ to hypertonic saline inhalation about the performance of inducing sputum for the diagnosis of pulmonary tuberculosis Source: International Congress 2015 – Management of TB: a patient focus Year: 2015 Response to empirical anti-tuberculosis treatment in patients with sputum smear-negative pulmonary tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 845s Year: 2006 Exposure to mycobacterium tuberculosis during bronchoscopy in patients with unexpected pulmonary tuberculosis Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis Year: 2016 Pulmonary tuberculosis with primary drug resistant mycobacterium tuberculosis -treatment outcomes Source: Eur Respir J 2004; 24: Suppl. 48, 657s Year: 2004 Paradoxical response during antibiotic treatment in patients with Mycobacterium avium complex lung disease Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020 Effect of airway clearance techniques on the efficacy of the sputum induction procedure Source: Eur Respir J 2005; 26: 904-908 Year: 2005 The utility of a serodiagnosis for mycobacterium avium complex pulmonary disease diagnosed by the single available bronchial wash Source: Eur Respir J 2004; 24: Suppl. 48, 206s Year: 2004 Usefulness of bronchial lavage for the diagnosis of pulmonary disease caused by mycobacterium avium-intracellulare complex (MAC) infection Source: Eur Respir J 2003; 22: Suppl. 45, 334s Year: 2003 Frequency of endobronchial tuberculosis in patients with active pulmonary tuberculosis is high Source: Eur Respir J 2004; 24: Suppl. 48, 33s Year: 2004 Effects of complex treatment with izofon of a pulmonary tuberculosis in children Source: Eur Respir J 2004; 24: Suppl. 48, 652s Year: 2004 Intravenous ozon in MDR pulmonary tuberculosis Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Development of mycobacterium tuberculosis additional drug resistance during chemotherapy of disseminated pulmonary tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 663s Year: 2007 Mycobacterium tuberculosis DNA detection in urine samples from pulmonary tuberculosis patients Source: Annual Congress 2008 - Genetics, immunology and microbiology of tuberculosis Year: 2008 Cough improves earlier than sputum after treatment initiation in hospitalised patients with pulmonary tuberculosis Source: Virtual Congress 2020 – Tuberculosis and adverse events in different populations Year: 2020 Clinical efficacy and safety of fluoroquinolone containing regimens in patients with Mycobacterium avium complex pulmonary disease Source: Eur Respir J, 55 (4) 1901240; 10.1183/13993003.01240-2019 Year: 2020